Key facts
- This page summarizes Jack Higgins's Form 4 filing for Immunome Inc. (IMNM).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Sep 2026, 16:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Gift
No transaction description listed
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
Footnote F2
The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.
Footnote F3
25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.